Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
about
Suicidal behavior and depression in smoking cessation treatmentsNicotine receptor partial agonists for smoking cessationPsychosocial interventions for smoking cessation in patients with coronary heart diseaseNicotine receptor partial agonists for smoking cessationPharmacological interventions for smoking cessation: an overview and network meta-analysisVarenicline: cardiovascular safetyVarenicline: quantifying the riskRisk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysisVarenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherenceHIV and smoking: associated risks and prevention strategiesEffect of Smoking Reduction Therapy on Smoking Cessation for Smokers without an Intention to Quit: An Updated Systematic Review and Meta-Analysis of Randomized ControlledVarenicline and cardiovascular adverse events: a perspective reviewCardiovascular effects of pharmacologic therapies for smoking cessationPreclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotypeMethodological issues in observational studies and non-randomized controlled trials in oncology in the era of big data.Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysisThe Past, Present, and Future of Nicotine Addiction TherapyTobacco addiction and the dysregulation of brain stress systems.Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort studyNew Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysisThe prevalence of and factors associated with the use of smoking cessation medication in Korea: trend between 2005-2011Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawalPharmacotherapy for smoking cessation: pharmacological principles and clinical practice.Identification of a new selective dopamine D4 receptor ligand.Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database.Patterns of nicotinic receptor antagonism II: cardiovascular effects in rats.Strategies to help a smoker who is struggling to quitAdapting smoking cessation treatment according to initial response to precessation nicotine patch.Pharmacological intervention of nicotine dependence.Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011"Tobacco dependence treatment makes no sense because"…: rebuttal of commonly-heard arguments against providing tobacco dependence treatment in the hospital setting.How confidence intervals become confusion intervalsVarenicline induced acute interstitial nephritis in the setting of idiopathic membranous glomerulonephritis.Treatment of tobacco dependence.Varenicline for smoking cessation: is it a heartbreaker?Smoking cessation in Asians: focus on vareniclineExtended varenicline treatment in a severe cardiopathic cigarette smoker: a case reportSafety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study
P2860
Q21089921-74D5126D-6D36-4AB9-B57A-9F73F668A12AQ24185773-DB659EF0-BD41-4E09-A0D1-C52BCB02D021Q24186549-004C106A-BBA2-4613-9E9B-B648CECB2C9DQ24200322-141F044F-B258-47FB-99DD-28809745D47DQ24202961-2593F1D3-8F5D-445A-80CA-39EA9537F968Q24602065-138B7BC5-696B-453F-B780-724FE7FAFCE1Q24602100-EC7FEB72-90BB-4C58-AAB2-30D677711895Q24628826-D79F54EA-CEF3-4AE3-8BCB-FEB576E002F6Q26751374-31B87584-C0E1-4459-B84A-0AF5664AD27CQ26772025-56D24B78-CA86-4384-8A68-F6BB9B2AC1EAQ26797327-6BAB9CE0-A9DC-4E93-A231-CF90887DCBAFQ26830506-BCD6321D-6D30-4F70-B9FF-3CBED5D9AAB0Q26849379-768DA4BE-1456-459C-B692-071E5F158D12Q27021772-FC039AA4-059C-4C31-9261-1D60F28C2834Q27691076-3575A220-8B3C-40B2-A14A-7D98B7A290A3Q28083649-03EB047D-BAAE-4EC5-A3D5-749DC9F36245Q28088508-40CF84C7-43CB-4299-8995-AD2484D34AF7Q28111988-0F9A2681-7449-4F3F-A2C7-FD8F21C64E4CQ28267175-46819E41-9173-4D8A-AE92-16B746D60CDAQ28277165-B1D83911-4534-4A78-BE90-153C62B3097EQ28303682-CD2B222C-5D7C-49F7-933E-2CB0F5AF2BE2Q28675725-C3F6742F-9206-4A26-9D66-CDC114952268Q30433175-01E60F00-EF7C-4276-9DC1-66661FCBEE7DQ33582051-C5E81881-C456-43DA-B725-1987FA3BE339Q33896124-95D9C15E-69F0-4CF8-986C-3EF8D16607EFQ34144971-66D62E84-0225-4EE3-9FB5-21C51C182B93Q34239996-40D761B9-5238-41E5-8A2D-35A0A4EA350AQ34306544-7CBEE089-9161-4C42-8E77-01F8B06845A7Q34342649-08578A14-87ED-48C4-9EA1-2F0871417253Q34401794-434B9087-1D81-44D9-89C9-596769A04DB2Q34676945-903DED67-5486-4DA3-88E1-BF8F360FCC5EQ34771486-90CBF03A-CD9F-4720-8B03-4873BBDCE9BBQ34892148-3A866FED-6251-4473-83B8-53DEC033AF62Q35028969-3B552A50-F88A-4B0B-B517-0B57ACC0543EQ35038376-893CC6F2-D428-47FB-8D75-1EF4686FF2FAQ35199252-2A4EACBA-38F8-4DA2-A424-4DE969C9814FQ35201184-C599BE46-D4C5-4200-90E2-21B7418FD66BQ35491463-AD1B5ED6-1B12-413D-9BCD-1424C8BB8569Q35599679-CAFE8BB7-5D81-4BB6-9486-F0E25046B7D5Q35623357-3A11C08A-F78C-4A20-AE75-1A46B32294EF
P2860
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Risk of serious adverse cardio ...... matic review and meta-analysis
@ast
Risk of serious adverse cardio ...... matic review and meta-analysis
@en
Risk of serious adverse cardio ...... matic review and meta-analysis
@nl
type
label
Risk of serious adverse cardio ...... matic review and meta-analysis
@ast
Risk of serious adverse cardio ...... matic review and meta-analysis
@en
Risk of serious adverse cardio ...... matic review and meta-analysis
@nl
prefLabel
Risk of serious adverse cardio ...... matic review and meta-analysis
@ast
Risk of serious adverse cardio ...... matic review and meta-analysis
@en
Risk of serious adverse cardio ...... matic review and meta-analysis
@nl
P2093
P2860
P31
P3181
P356
P1476
Risk of serious adverse cardio ...... matic review and meta-analysis
@en
P2093
Curt D Furberg
John G Spangler
Yoon K Loke
P2860
P304
P3181
P356
10.1503/CMAJ.110218
P407
P50
P577
2011-09-06T00:00:00Z